Business Overview: Bio Essence Corp. (OTC: BIOE)

---

Executive Summary

Bio Essence Corp. is a small, California-incorporated (2000) herbal health, diet, and nutrition company headquartered in Irvine, California. Historically the company manufactured and sold traditional Chinese medicine (TCM) products — single herbs, granules, pills, and tablets — alongside specially formulated dietary supplements and medical food, through wholly-owned manufacturing and distribution subsidiaries.

That vertically-integrated structure no longer exists. Across December 2023 and March 2024, Bio Essence sold both of its operating subsidiaries — Bio Essence Pharmaceutical (manufacturing, sold for $300,000) and Bio Essence Herbal Essentials (branded distribution, sold for $400,000) — and dissolved a planned prescription-medicine subsidiary, McBE Pharma, that never began operating. What remains is a four-employee parent company that now earns revenue almost entirely by providing original equipment manufacturer (OEM) services to third parties, having outsourced its own manufacturing. It matters mainly as a cautionary, real-world illustration of a micro-cap company that shed its branded operations and is now a thin pass-through OEM service provider with a going-concern qualification from its auditor.

---

1. Core Business Model & How They Work

Bio Essence no longer designs, brands, or distributes its own supplement products at meaningful scale. Instead, it coordinates OEM manufacturing services for other companies' herbal and nutritional products, using third-party manufacturing capacity rather than its own (divested) plant.

[ Third-party brand/customer need ] ➡️ [ Bio Essence OEM coordination/services ] ➡️ [ Outsourced manufacturing ] ➡️ [ Delivery to customer ] ➡️ [ OEM service fee revenue ]

Product sales (selling Bio Essence's own branded goods) fell to $0 in 2025, down from a already-small $37,415 in 2024 — effectively confirming that the legacy branded-products business is now wound down, and that OEM services are the entirety of the ongoing business.

---

2. Business Segments

The company does not report formal operating segments; FY2025 revenue breaks down only by type:

┌────────────────────────────────┐
│         Bio Essence Corp.       │
└────────────────┬─────────────────┘
                  │
   ┌──────────────┼───────────────────┐
   ▼                                   ▼
┌─────────────────────────┐   ┌─────────────────────┐
│   OEM Services           │   │  Product Sales /      │
│   ~99.9% of 2025 revenue │   │  Shipping & Delivery  │
│   ($1,896,350)            │   │  (~$1,216; $0 product)│
└─────────────────────────┘   └─────────────────────┘

Revenue growth in 2025 (to $1.90 million from $0.32 million in 2024) was driven largely by three new major OEM customers, which is a double-edged indicator: it shows the pivot to OEM services is gaining real traction, but it also means current revenue is highly concentrated and could reverse quickly if any one of those relationships ends.

---

3. Product Portfolio

---

4. Competitive Landscape

Bio Essence's 10-K contains no discussion of named competitors or competitive positioning — itself a telling signal for a company of this size. The herbal-supplement and nutraceutical contract-manufacturing space is fragmented and populated by far larger, better-capitalized OEM/private-label manufacturers (particularly in the U.S. and China) that can offer customers more scale, lower unit costs, and broader regulatory/quality certifications. Bio Essence, having sold off its own manufacturing capacity, is now a small intermediary in that same market rather than a vertically-integrated producer — a structurally weaker position than either a scaled OEM manufacturer or a differentiated branded-supplement company.

---

5. Strategic Strengths & Risks

Strengths are genuinely difficult to identify from the filing: the company holds no patents or proprietary formulations of note (its branded TCM manufacturing and distribution businesses were both divested), has no disclosed brand equity remaining in the market, and does not claim any cost, scale, or technology edge. Its one real asset is a set of new OEM customer relationships that produced real revenue growth in 2025 — but three customers driving nearly all of that growth is concentration, not moat.

Risks are numerous and specific: a going-concern qualification from the company's auditor; a stockholders' deficit of $2.07 million and working-capital deficit of $2.02 million at year-end 2025 against zero cash on hand; management's own estimate that it needs roughly $1.2 million over the next 12 months to continue operating; an active lawsuit from a former landlord/lab-services counterparty (Stason Industrial Corporation and Stason Pharmaceuticals) seeking ~$1.5 million; heavy reliance on loans from its controlling shareholder; 87.5% combined share ownership concentrated in two individuals (Jian Yang ~55.3%, Yin Yan ~35.2%); and management's own conclusion that disclosure controls and internal controls over financial reporting were not effective. There is no audit committee financial expert, no code of ethics, and no equity compensation plan.

---

6. Financial Overview

---

7. Summary Conclusion

Bio Essence is best understood not as an operating herbal-products company anymore, but as a thinly-staffed OEM services pass-through that divested its manufacturing and branded-distribution businesses in 2023–2024 and pivoted, almost by necessity, to coordinating third-party contract manufacturing for a small and concentrated set of new customers. The 2025 revenue growth is real but fragile — built on three customers, with zero cash on hand, an explicit going-concern warning, and ineffective internal controls. Absent any patents, brand equity, scale, or disclosed competitive positioning, the company has essentially no structural moat; its near-term survival depends on continued related-party funding and whether its new OEM relationships prove durable rather than one-off.